PARP Inhibitors in Ovarian Cancer: A Review

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, w...

Full description

Saved in:

Bibliographic Details
Published in:	Targeted oncology Vol. 18; no. 4; pp. 471 - 503
Main Authors:	O’Malley, David M., Krivak, Thomas C., Kabil, Nashwa, Munley, Jiefen, Moore, Kathleen N.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01.07.2023 Springer Nature B.V
Subjects:	Bevacizumab - therapeutic use Biomedicine Carcinoma, Ovarian Epithelial - drug therapy Female Humans Medicine Medicine & Public Health Monoclonal antibodies Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Quality of Life Review Review Article Targeted cancer therapy United States > US
ISSN:	1776-2596, 1776-260X, 1776-260X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!